Bold claim: Genetic risk can forecast how bad inflammatory bowel disease will become for an individual, potentially guiding earlier, smarter treatment. But here’s the twist that often gets overlooked: the journey from genes to a patient’s daily life is complex and still evolving.
There are about 60,000 Danes living with chronic inflammatory bowel disease. For some, discomfort is mild; for others, the condition follows a harsher path that may require surgery and a stoma. Added stress comes from the fear of urgent bathroom needs that can keep people from leaving home.
A central problem today is the difficulty of predicting disease progression for each patient. As a result, many individuals receive treatments that are either overly aggressive or insufficient, and crucial windows for preemptive intervention—before substantial intestinal damage occurs—are often missed.
A new Danish study from the DNRF Center of Excellence PREDICT at Aalborg University suggests that it is possible to determine at diagnosis whether a patient is likely to experience a severe disease course. The researchers found that a higher genetic risk for the disease correlates with a greater chance of a severe disease trajectory.
This work marks a meaningful step toward personalized care. By integrating national registry data, clinical records, and material from Denmark’s National Biobank, the team analyzed almost 8,300 individuals with chronic inflammatory bowel disease. The findings have been published in the prominent international journal Gastroenterology.
Today, there is no cure for chronic inflammatory bowel disease. Treatments can control symptoms or, in some cases, remove the affected section of the intestine surgically. However, relapses are common, treatments can require changes, and the disease course varies substantially from person to person.
Marie Vibeke Vestergaard, Study Lead Author and Research Assistant at Aalborg University, notes, “We still lack a reliable clinical tool to choose the most appropriate strategy for each patient. These new insights represent important early steps toward genuinely personalized treatment.”
Knowledge of biological markers remains incomplete. The observed link between genetics and disease severity is supported by prior work from the same group, which showed that the gene HLA-DRB1*01:03 significantly increases the likelihood of major surgery for ulcerative colitis.
Related stories
- More iron, less damage: why chronic lung infections persist
- Healthy diets link to longer life regardless of longevity genes
- Genetic study links vitamin B1 metabolism to gut motility and IBS risk
While the current findings are early steps, more research is needed to identify key biological markers that inform prevention and the sequencing of individual disease trajectories. Ongoing studies will test which medications and treatment strategies suit specific patient subgroups.
“We know genetics is only one piece of a larger puzzle that shapes disease onset and severity,” Vestergaard adds. “We will continue probing the biology to help clinicians offer more precise, personalized treatments that could lead to milder disease courses for more patients.”
Source:
Vestergaard, M. V., et al. (2026). Genetic Risk of Inflammatory Bowel Disease Is Associated With Disease Course Severity. Scientific Reports. DOI: 10.1053/j.gastro.2025.09.018
